Small Interfering RNA (siRNA) Market Forecast with Growth and Trends
According to Rohan Patil, who specializes in life sciences with extensive expertise in cell and gene therapy, corporate strategy formulation, and commercial pipeline evaluation, with 5+ years of experience in market research and industry analysis, extensive research indicates strong growth opportunities in the small interfering RNA (siRNA) market. The global small interfering RNA (siRNA) market size was estimated at USD 3.9 billion in 2025 and is predicted to increase from USD 4.52 billion in 2026 to approximately USD 16.91 billion by 2035, expanding at a CAGR of 15.8% from 2026 to 2035. His analysis highlights key market drivers, trends, or technologies such as the development of advanced lipid nanoparticle (LNP) and GalNAc delivery conjugates, a rapidly growing pipeline for oncology and rare genetic disorders, and a massive surge in strategic biopharma partnerships. The research also examines the competitive strategies of key industry participants, including Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Sanofi Genzyme, Novartis, Silence Therapeutics, and Sirius Therapeutics, to sustain market footprints through proprietary manufacturing platforms and advanced clinical trial developments.
Last Updated : 14 July 2026
Category: Life Sciences
Insight Code: 6860
Format: PDF / PPT / Excel